Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients.

We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. 

Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Mubadala Capital Ventures

Invus

Abu Dhabi Growth Fund

Altitude Life Science Ventures

Amgen

EXOR N.V.

ARCH Venture Partners

Newpath Management

Polaris Partners

F-Prime Capital

Neumora

We are delighted to welcome Kaya Pai Panandiker as Chief Commercial Officer. Kaya brings to Neumora extensive commercial strategy and execution expertise, having led the launches of multiple neuropsychiatry products throughout her career. Read more: https://lnkd.in/ex-Zr2JP

Each year, our CEO Excellence Awards celebrate individuals or cross functional teams who demonstrate our values every day by achieving the extraordinary, creating value and doing what is right. We were thrilled to recognize our 2023 winners, Karla Zeitz, Jason Morton, Partha Mudipalli, Ph.D., Hong Ji, Santnu P., Michael Eyre, Heather Stemper, Palwasha T., Leanna Bui, Tash Barrow, Kelly Voong and Anh Le Vynh, for their outstanding contributions to Neumora. Thank you for your unwavering dedication to this work!

We’ve had a great week connecting with #JPM24 attendees! #ICYMI, check out CEO Henry Gosebruch’s podium presentation, outlining the exciting year ahead and our industry-leading pipeline. We look forward to continuing to pioneer a new era in brain disease and lead innovation in brain health throughout 2024. https://lnkd.in/eRFzBnEY

Neumora was founded to improve the lives of people living with brain diseases. To do that, we’ve built an industry-leading pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action. Learn more about our pipeline below. #JPM24

We are heading to San Francisco next week for #JPM24! CEO Henry Gosebruch will present on Monday, January 8 at 11:15AM PT. Learn more below. https://lnkd.in/ePiU73Zx

We are headed into this holiday season filled with gratitude for those around us. Wishing you the happiest of holidays from all of us at Neumora!

A recent NAMI study found that 64% of people with a mental illness said holidays make their conditions worse. It's important to put yourself first and prioritize your well-being, especially during the holiday season. We're sharing some of our favorite tips from NAMI and The Jed Foundation (JED) on how to reduce stress and maintain good #mentalhealth in the coming weeks. In an emergency, dial 988 to reach the suicide and crisis lifeline.

We are pleased to welcome Jason G. Duncan to Neumora as Chief Legal Officer. Jason's decades of legal, compliance, development and operations experience will be invaluable to our team as we continue to progress our pipeline. Read more: https://lnkd.in/eUdk_Gkr

We had a great time in Tampa at #ACNP2023, where Dr. Sanjay Mathew presented data from our #MDD program. It was great to connect with so many neuropsych thought leaders!

Today we announced IND clearance and the initiation of a Phase 1 study for NMRA-266, our M4 positive allosteric modulator. Read more here. https://lnkd.in/e_Vz_cjb

Domain Not Resolving

Google Tag Manager

HSTS

Google Font API

Google Analytics

Google Analytics 4

jsDelivr

Google Universal Analytics

Cloudflare JS

Google

VP, Associate General Counsel

Aaron Schohn

Chief People Officer

Julie Person

Chief Medical Officer

Mr. Michael Gold

VP, Head of Regulatory Affairs

Alix Alderman

VP, Business Development

Elizabeth Birch

VP, Head of IP

Erik Birkeneder

VP, Head of Corporate Development

Evan Gibson

Head of Portfolio Planning, Program and Alliance Management, Senior Vice President

Huw Tanner

VP of Preclinical Sciences

Lori Orden

Senior Vice President, Business Technology & Digital Health

Pablo Gersberg

Robert Nelsen

Maykin Ho

Matthew Fust

Stacie Weninger

Kristina Burow

Alaa Halawa

Henry Gosebruch

President and CEO

Kaya Pai Panandiker

Chief Commercial Officer (CCO)

Bill Aurora

Chief External Affairs Officer

Carol Suh

Co-founder & VP

Jason G. Duncan

Chief Legal Officer

Mike Poole

Co-founder and Advisor

Jane Tiller

East Coast Public Companies With Less Than $1B in Revenue

Greater Boston Area Biotechnology Companies

East Coast Biotechnology Companies

Biotechnology Public Companies With Less Than $50M in Revenue

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Series B - Neumora Therapeutics

Corporate Round - Neumora Therapeutics

Series A - Neumora Therapeutics

Venture Round - Neumora Therapeutics

Watertown

Massachusetts

United States

North America

Neumora Therapeutics

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Neumora Therapeutics GAAP EPS of -$0.45 misses by $0.06 (NASDAQ:NMRA)

Neumora Therapeutics Officer Sells Shares

Neumora Therapeutics files automatic mixed securities shelf

5 Neuro Data Readouts to Watch in the Second Half of 2024

Neumora Therapeutics announces initiation of Phase 1b study of NMRA-511

Study Reveals Ancestry-Related Differences in Postmortem Brain Gene Activity

Parkinson's UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson's drug

We're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash Wisely

An investigational oral medication in Phase 3 development for treating Major Depressive Disorder by modulating dopamine and reward processing pathways.

A program targeting the NLRP3 pathway, under investigation for its potential in treating neurodegenerative diseases.

A program focused on activating GCASE, under investigation for its potential benefits in neurodegenerative diseases.

Neumora conducts clinical trials to evaluate the safety and effectiveness of new therapies for brain diseases.

New Zealand

Oceania

India

Asia

Croatia

Europe

Monument Therapeutics is a biotechnology company with a focus on neuroscience and psychiatry. The company develops treatments for serious diseases of the central nervous system using a precision medicine approach, which involves the use of proprietary digital biomarkers to identify patients with specific neurobiological characteristics and match them with targeted compounds.

Monument Therapeutics

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company's pipeline includes novel treatments targeting various CNS diseases with a precision medicine approach.

Senior Director, Electrophysiology

Director

Director, Electrophysiology

Research Assistant Professor

Program Director

Research Scientist

Graduate Student

Senior Director

Tarek Deeb

Director, Toxicology

Principal Scientist

Senior Research Operations Manager

Research Operations Manager

Consultant

Senior Scientist

Scientist

Karla Zeitz

Director, Clinical Operation Program Excellence

Director Clinical Operations

Director of Clinical Operations

Clinical Project Lead/Clinical Trial Manager

Clinical Project Manager

Clinical Project Lead, Clinical Operations

Clinical  Research Program Coordinator

Lead Project Manager

Study Coordinator – Data Management

Director, Clinical Operations Program Excellence

Adriana Manari

Director, Program Management

Director, Program Management/ Asset Operational Lead

Sage Therapeutics

Director, Alliance Management

Associate Director, Alliance Management

Associate Director, Program Management

Takeda Oncology

Global Launch Project Manager

Manager, Marketing Effectiveness

Project Coordinator, New Product Specialist

Experienced Biotech Project, Program, and Alliance Manager

Kate Carioli

Director of Biostatistics

Associate Director Biostatistics

Associate Director of Biostatistics

Principal Biostatistician

Sr. Biostatistician II

Biostatistician

postdoctoral associate

Director of Biostatistics at Neumora Therapeutics

Xueping Zhang

Senior Research Associate

Research Associate II

Intern

Director, Discovery Chemistry

Anne-Marie Beausoleil

Chief Legal Officer | General Counsel & Secretary | Head of Program Management

General Counsel and Secretary

General Counsel, Americas

Vice President, Head of Compliance and Legal, North America

Associate General Counsel, Neurology and Discovery

Senior Therapeutic Area Counsel, Neurology

Therapeutic Area Counsel, Neurology

Associate, Business Group

Associate, Corporate and Financial Markets Groups

Life Sciences Executive | Enterprise Leader | Chief Legal Officer

Jason Duncan

Director, Quality Control

Associate Director

Lab Manager

Director, Quality Control at Neumora

Heather Stemper

Head of Analytical Development and Quality Control

Director, Analytical development and quality control

Hong Ji

Chief Human Resources Officer

SVP, Head of Human Resources

VP, Talent

Head of Human Resources (Interim)

Director, Human Resource Business Partner

Global Head of Talent Management & Leadership Development (Shire)

Global Head Of Talent Management & Leadership Development

Director and Lead HR Business Partner

Associate Director, Senior Human Resources Business Partner

Human Resource Generalist

Recruiting Coordinator

Amy Sullivan

Senior Director, Manufacturing Operations

Director, CMC Development

Director, Technical Operations

Director, Process Engineering and Operations, Chemical Process Research & Development

news impact assignment basic	general	Mar 5, 2024 2:37 AM	304af5ea
public peers	general
news daily refresh	general	Sep 3, 2024 1:30 PM	a0ade48e
news processing daily refresh	general	Sep 3, 2024 2:50 PM	eb5cdb40
news impact assignment daily	general	Sep 2, 2024 11:37 PM	03162d9c
news processing basic	general	Mar 5, 2024 2:37 AM	8bb3beaa
company summary	general	Aug 30, 2024 6:31 PM	b5be7711
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	b634aae9
crunchbase profile	general	Nov 25, 2024 11:36 AM	acc2a225
li profile	general	Mar 5, 2024 2:37 AM	b14c2ef0
translate crunchbase fundingrounds	general	Nov 25, 2024 2:18 PM	a26fffcc
peers	general
news basic	general	Mar 5, 2024 2:37 AM	d23df3c2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEUMORATX

Neumora Therapeutics, Inc.

Last Close

9.69

22/11 21:00

Market Cap

1.72B

Beta: -

Volume Today

490.17K

Avg: -